Jafron BiomedicalLtd マネジメント

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Fan Dong	Chairman of Board of Directors & GM	no data	CN¥3.74m	45.86% CN¥ 10.9b
Xueyun Liao	Director & Financial Director	1.6yrs	CN¥500.50k	0.019% CN¥ 4.5m
De Zhi Li	Deputy General Manager	no data	CN¥865.40k	0.46% CN¥ 108.4m
Xian Min Tang	Deputy GM & Director	no data	CN¥2.65m	2.76% CN¥ 653.1m
Aijun Wu	Deputy General Manager	4.5yrs	CN¥2.44m	0.031% CN¥ 7.4m
Rui Wang	General Manager	1.2yrs	CN¥510.40k	データなし
Cong Huang	Board Secretary	2.2yrs	CN¥455.20k	0.00044% CN¥ 104.3k

1.9yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 300529の経営陣は経験豊富とはみなされません ( 1.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Fan Dong	Chairman of Board of Directors & GM	14.2yrs	CN¥3.74m	45.86% CN¥ 10.9b
Xueyun Liao	Director & Financial Director	less than a year	CN¥500.50k	0.019% CN¥ 4.5m
Xian Min Tang	Deputy GM & Director	14.2yrs	CN¥2.65m	2.76% CN¥ 653.1m
Claudio Ronco	Member of Global Advisory Board	3.4yrs	データなし	データなし
Feng Li	Non-Independent Director	4.6yrs	CN¥1.08m	0.099% CN¥ 23.4m
Xiaohong Peng	Chairman of Supervisory Board	4.6yrs	データなし	データなし
Wen Lei	Non-Independent Director	4.6yrs	CN¥177.20k	データなし
Rinaldo Bellomo	Member of Global Advisory Board	3.4yrs	データなし	データなし
Thomas Rimmelé	Member of Global Advisory Board	3.4yrs	データなし	データなし
John Prowle	Member of Global Advisory Board	3.4yrs	データなし	データなし
Antoine Schneider	Member of Global Advisory Board	3.4yrs	データなし	データなし
Olivier Joannes-Boyau	Member of Global Advisory Board	3.4yrs	データなし	データなし

3.4yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: 300529の取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Jafron BiomedicalLtd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Now 27% overvalued after recent price rise

Consensus EPS estimates increase by 34%

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.18 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

New minor risk - Share price stability

Jafron Biomedical Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥84.63

New 90-day low: CN¥64.16

Market pulls back on stock over the past week

Price target raised to CN¥95.66

New 90-day high: CN¥78.75

Price target raised to CN¥52.96

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

マネジメント基準チェック /24